COMMUNIQUÉS West-GlobeNewswire

Nema Health Expands Access to Specialized PTSD Treatment Through Evernorth Behavioral Health Network
15/10/2026
New in-network agreement makes evidence-based trauma treatment more accessible to eligible Cigna Healthcare and Evernorth members NEW HAVEN, Conn., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Nema Health, a virtual specialty care [...]
Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer
15/10/2026
Internally-derived candidate targets wild-type androgen receptor and clinically relevant variants implicated in resistance to conventional prostate cancer therapies MILLBRAE, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- [...]
Callio Therapeutics Wins Best New ADC Drug Developer at the 13th World ADC Awards, Presents Across Five Sessions at World ADC San Diego
15/10/2026
Callio leaders delivered three presentations and two panel discussions on dual-payload ADC resistance, manufacturability, linker design, and the path to next-generation ADCs SAN DIEGO, SEATTLE and SINGAPORE, Oct. 15, [...]
Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy
15/10/2026
LB2501 is an off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells directly within the patient after a single infusion, making it the first known dual-targeting in vivo CAR-T [...]
ORYZON further strengthens vafidemstat’s patent portfolio with new decisions to grant
15/10/2026
New patent allowances in South Korea, Mexico, New Zealand and the Philippines Further expand IP protection across BPD, ASD, aggression and social withdrawal MADRID and CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE [...]
Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis
15/10/2026
Eupraxia reached its target enrollment of 120 patients in the Phase 2b placebo-controlled blinded portion of the RESOLVE trial The Company has a statistical team who are doing periodic reviews of the unblinded data to [...]
Jyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug Candidates
15/10/2026
New Taipei City, Taiwan, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization [...]
Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026
15/10/2026
SEATTLE, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results [...]
Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone
15/10/2026
Leading Healthcare Investors, includ ing Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital Management and other prominent healthcare specialists and mutual funds invest $200 million in [...]
DaltonTx awarded grant to accelerate AI-powered tuberculosis drug discovery
15/10/2026
Funding from the Gates Foundation supports development of open-access AI models, workflows and datasets to help researchers identify new tuberculosis (TB) targets for faster and more cost-effective drug discovery [...]
iOnctura appoints Paul Sekhri as Chair of its Board of Directors
15/10/2026
Paul Sekhri is a life science executive with more than 35 years of experience building and leading companies from early development through commercialization Appointment comes as iOnctura prepares for late-stage [...]
Mission Therapeutics doses first Parkinson’s patient in Phase 1b study of potential disease-modifying treatment MTX325
15/10/2026
MTX325 is a first-in-class, highly potent, orally bioavailable, brain-penetrant USP30 inhibitor designed to modify the course of Parkinson’s by improving mitochondrial control Phase 1b ‘MTX325-101’ study – taking place [...]
EXIT-CVD research consortium launches clinical studies to transform cardiovascular care across Europe
15/10/2026
October 15, 2026 Five-year research project unites 42 public and private partners across 17 countries to conduct 22 clinical studies involving 14,000+ patients; first patients will be enrolled this month Project aims to [...]
invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal
15/10/2026
invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal Publication in Molecular Therapy Oncology reports Phase 1 data from 17 patients with advanced, treatment- [...]
Kuros Biosciences increases 2026 annual guidance, The company reports 40% year-over-year increase in sales in the first nine months of 2026
15/10/2026
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences increases 2026 annual guidance The company reports 40% year-over-year increase in sales in the first nine months of 2026 Schlieren ( [...]
IBA sélectionnée pour équiper l’expansion aux États-Unis d’un leader de la production de radiopharmaceutiques avec une commande de 12 systèmes Cyclone® KIUBE
15/10/2026
IBA devient le fournisseur privilégié pour équiper de 12 systèmes un réseau national de production de radiopharmaceutiques TEP, sécurisant des capacités de production en anticipation de la demande dans les domaines du [...]
IBA selected to support the US expansion of a leading radiopharmaceutical producer with an order for 12 Cyclone® KIUBE systems
15/10/2026
IBA is preferred supplier for a 12-system national PET radiopharmaceutical production network, securing capacity ahead of demand across diagnostics and theranostics Louvain-la-Neuve, Belgium – October 15, 2026, 7 a.m [...]
argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
15/10/2026
October 15, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will host a conference call and audio webcast on Thursday, October 22, [...]
OSE Immunotherapeutics présentera lors de la 10ème Chardan Annual Healthcare Conference
15/10/2026
Nantes, France, 15 octobre 2026 – 7h30 CEST – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnémo: OSE) , une société de biotechnologie au stade clinique développant des thérapies first-in-class en immuno-oncologie [...]

Pages